Produces the Impella product line, the world's smallest and minimally invasive micro blood pump

Developer and manufacturer of mechanical circulatory support devices, offering a continuum of care to heart failure patients

With headquarters in Danvers, Massachusetts, Abiomed (Nasdaq: ABMD) developed products that were designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its main family of products, Impella, was used in the cardiac catheterization lab by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who were in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company’s main products included Impella 2.5, Impella 5.0, Impella CP, Impella RP, and Symphony. The Company was founded in 1981, sold its products nationally and internationally, and had over 500 employees. Abiomed was acquired by Johnson & Johnson for a total price of $16.6 billion, the largest medtech transaction of 2022.

  • Danvers, MA

  • Contact:
    Marty Sutter
  • Formerly Known As: Impella CardioSystems
  • Acquisition
  • Acquired by: Johnson & Johnson
  • Logo

Related News

“EW has become a partner and advisor to Abiomed. We value the strategic guidance we receive from their team on investment and business decisions.”

Michael R. Minogue

Chairman, President and CEO, Abiomed

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.